Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009046984 - HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES

Publication Number WO/2009/046984
Publication Date 16.04.2009
International Application No. PCT/EP2008/008544
International Filing Date 09.10.2008
Chapter 2 Demand Filed 01.07.2009
IPC
C12N 15/10 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
A61K 39/21 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C12N 2740/16134
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • TECHNOLOGIE INTEGRALE LTD. [AT]/[AT] (AllExceptUS)
  • FILINOVA, Elena, Yu. [RU]/[RU] (UsOnly)
Inventors
  • FILINOVA, Elena, Yu.
Agents
  • BECKER KURIG STRAUS
Priority Data
60/978,53609.10.2007US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES
(FR) VACCIN PRÉVENTIF CONTRE VIH À BASE D'ANTICORPS SPÉCIFIQUE DE VIH
Abstract
(EN) The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response in an individual, which bind to existing in a current epidemiologic cohort HIV-subtypes and mutants selected after antiretroviral therapy. The present invention also relates to HIV-1 peptides/polypeptides/proteins selection with reverse panning technique, LC mass spectrometry identification of HIV-1 env peptides/polypeptides/proteins, gp120 and its fragment in particular, production of recombinant HIV-1 env peptides in suitable host with necessary glycosylation - L. tarentolae and using sterically stabilized liposomes (SSL) as an adjuvant-carrier for HIV-specific immune boost composition.
(FR) La présente invention concerne un procédé de production d'un vaccin contre le VIH, de prévention d'une infection à VIH et/ou de prévention du développement d'une infection à VIH chez un individu. En particulier, la présente invention concerne la formation d'anticorps spécifiques de VIH capables de reconnaître et de se lier substantiellement à toutes les isoformes de VIH en tant que réponse immunitaire chez un individu, qui se lient à des sous-types de VIH existants dans une cohorte épidémiologique actuelle et des mutants choisis après un traitement antirétroviral. La présente invention concerne également la sélection de peptides/polypeptides/protéines de VIH-1 par une technique d'adhérence inverse, identification par spectrométrie de masse LC de peptides/polypeptides/protéines de VIH-1 env, gp120 et leur fragment, en particulier, la production de peptides de VIH-1 env recombinants chez un hôte approprié avec une glycosylation nécessaire - L. tarentolae et en utilisant des liposomes stériquement stabilisés (SSL) comme adjuvant-véhicule pour la composition de stimulation immunitaire spécifique de VIH.
Related patent documents
RU2010116849This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau